>Specially Designed Proteins for COVID-19 Serological Test Development
The pandemic caused by SARS-CoV-2 presents a serious global public health emergency. The number of COVID-19 cases and deaths predicted to be rising in the coming weeks and months in the majority of countries. Accurate diagnosis of COVID-19 is not only essential to carry out appropriate patient care but also take timely quarantine measures to limit virus spread.
The widely employed etiological diagnosis of SARS-CoV-2 infection relies on a nucleic acid test with Real Time-PCR (RT-PCR) using specimens collected via nasopharyngeal swab. However, the results show that the positive detection rate of RT-PCR in clinical and epidemiological suspected COVID-19 cases is about 50% due to some factors such as sample quality, virus infection site and sampling time, etc.
Serological tests can be used to identify whether people have been exposed to a particular pathogen by looking for the presence of antibodies that are produced in response to infections. In compared with RT-PCR, serological test usually has the advantages of convenient and stable sample collection, easy realization of high throughput and small workload.
Therefore, the demand for serological tests of SARS-CoV-2 is increasing rapidly in order to improve the accuracy of clinical diagnosis and better quantify the number of cases of COVID-19, including those that may be asymptomatic or have recovered.
As of May 17, 12 serological test kits for SARS-CoV-2 have received Emergency Use Authorization from FDA, including colloidal gold immunoassay, chemiluminescence immunoassay and ELISA.
The antigens of SARS-CoV-2 are employed in these commercial kits to detect the antibodies present in serum of virus-infected patients. To improve the sensitivity and specificity of serological test kits, antigens derived from the SARS-CoV-2 Spike protein and Nucleocapsid protein are recombinantly produced and used in the antibody test cassette.
ACROBiosystems has developed SARS-CoV-2 antigens specifically designed and optimized for serological test kits：
Customized formulation available
Capable of supplying in bulk order
Multiple tags and biotin label version ready to choose
5+ RBD mutant proteins
Fig.1 Immobilized SARS-CoV-2 Nucleocapsid protein, His Tag (Cat. No. NUN-C51H9) at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 NP Antibody, Rabbit MAb (CLN27) with a linear range of 0.02-0.3 ng/mL.
|Molecule||Cat. No.||Product Description|
|S1 protein||S1N-C52H3||SARS-CoV-2 (COVID-19) S1 protein, His Tag|
|S1N-C82E8||Biotinylated SARS-CoV-2 (COVID-19) S1 protein, His,Avitag™ (MALS verified)|
|S1N-S52H5||SARS S1 protein, His Tag (MALS verified)|
|S1N-C52H4||SARS-CoV-2 (COVID-19) S1 protein, His Tag (MALS verified)|
|S1N-C5255||SARS-CoV-2 (COVID-19) S1 protein, Fc Tag|
|S1N-C5257||SARS-CoV-2 (COVID-19) S1 protein, Mouse IgG2a Fc Tag|
|S protein RBD||SPD-C82E9||Biotinylated SARS-CoV-2 (COVID-19) S protein RBD, His,Avitag™ (MALS verified)|
|SPD-C5255||SARS-CoV-2 (COVID-19) S protein RBD, Fc Tag (MALS verified)|
|SPD-S52H6||SARS S protein RBD, His Tag (MALS verified)|
|SPD-C52H3||SARS-CoV-2 (COVID-19) S protein RBD, His Tag (MALS verified)|
|SPD-C5259||SARS-CoV-2 (COVID-19) S protein RBD, Mouse IgG2a Fc Tag|
|SPD-S52H4||SARS-CoV-2 (COVID-19) S protein RBD (V367F), His Tag|
|SPD-S52H5||SARS-CoV-2 (COVID-19) S protein RBD (N354D), His Tag|
|SPD-S52H7||SARS-CoV-2 (COVID-19) S protein RBD (W436R), His Tag|
|SPD-S52H8||SARS-CoV-2 (COVID-19) S protein RBD (R408I), His Tag|
|SPD-S52H3||SARS-CoV-2 (COVID-19) S protein RBD (N354D, D364Y), His Tag|
|Nucleocapsid protein||NUN-C51H9||SARS-CoV-2 (COVID-19) Nucleocapsid protein, His Tag|
|NUN-C5227||SARS-CoV-2 (COVID-19) Nucleocapsid protein, His Tag|
|NUN-C81Q6||Biotinylated SARS-CoV-2 (COVID-19) Nucleocapsid protein, His,Avitag™|
This web search service is supported by Google Inc.